

PRODUCT MONOGRAPH

Pr APO-CEFADROXIL

Cefadroxil Capsules USP

(as cefadroxil monohydrate)

500 mg

ANTIBIOTIC

**APOTEX INC.
150 Signet Drive,
Toronto, Ontario
M9L 1T9**

**DATE OF REVISION:
September 1, 2020**

Control Number: 242517

PRODUCT MONOGRAPH

Pr **APO-CEFADROXIL**

Cefadroxil Capsules USP
(as cefadroxil monohydrate)

THERAPEUTIC CLASSIFICATION

Antibiotic

ACTIONS AND CLINICAL PHARMACOLOGY

APO-CEFADROXIL (Cefadroxil) is a cephalosporin which exhibits bactericidal activity. *In vitro* studies have demonstrated that the antibacterial activity of the cephalosporins is a result of their ability to inhibit mucopeptide synthesis in the bacterial cell wall.

Comparative Bioavailability

A randomized, two-way, cross-over, single-dose bioavailability study was conducted in healthy, adult, male subjects. The bioavailability of APO-CEFADROXIL 500 mg capsules relative to Duricef® 500 mg capsules was determined following a single oral dose of 1000 mg (2 x 500 mg capsules). The average values of the pharmacokinetic parameters determined for each of the formulations are listed in the following table for the 14 subjects completing the study.

Summary Table of the Comparative Bioavailability Data Apo-Cefadroxil (Dose: 2 x 500 mg) From Measured Data			
Parameter	Geometric Mean** Arithmetic Mean (CV%)		Ratio of Geometric Means (%)
	Apo-Cefadroxil	Duricef®†	
AUC _T (mcg•hr/mL)	90.925 94.173 (18)	92.068 95.462 (18)	98.8
AUC _I (mcg•hr/mL)	92.703 95.851 (18)	93.405 96.814 (18)	99.2
C _{max} (mcg/mL)	29.730 31.135 (17)	28.554 29.444 (15)	104.1
T _{max} (hr)*	1.39 (39)	1.64 (42)	--
t _{1/2} (hr)*	1.60 (11)	1.61 (9)	--
Arithmetic means (CV%). The least squares estimate of the geometric means for AUC _T , AUC _I , and C _{max} parameters. Duricef® is manufactured by Bristol-Myers Squibb Inc., and was purchased in Canada.			

INDICATIONS AND CLINICAL USE

APO-CEFADROXIL (cefadroxil) is indicated for the treatment of the following infections when caused by susceptible strains of the organisms indicated:

- Acute uncomplicated urinary tract infections when caused by *E. coli*, Klebsiella species and some strains of *Proteus mirabilis*.
- Skin and skin structure infections caused by *Staphylococcus aureus* and/or Group A β -hemolytic streptococci.
- Acute pharyngitis-tonsillitis, when caused by Group A β -hemolytic streptococci.
- Lower respiratory tract infections, including pneumonia, caused by *S. pneumoniae* (*D. pneumoniae*), *S. Pyogenes* (Group A β -hemolytic streptococci), *K. pneumoniae* and *S. aureus*.

Prior to and during therapy, appropriate bacteriological studies should be performed in order to identify and determine the susceptibility of the causative organism(s).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of APO-CEFADROXIL and other antibacterial drugs, APO-CEFADROXIL should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

CONTRAINDICATIONS

APO-CEFADROXIL (cefadroxil) is contraindicated in patients with a known hypersensitivity to the cephalosporin group of antibiotics.

WARNINGS

Cephalosporin antibiotics (including APO-CEFADROXIL (cefadroxil)) should be administered with great caution to patients with known hypersensitivity to the penicillins. Clinical and laboratory evidence exists of cross-allergenicity between the penicillin and cephalosporin groups of antibiotics. There have been reports of patients who have had reactions to both classes of antibiotics (including fatal anaphylactoid reactions after parenteral administration).

APO-CEFADROXIL should be administered with caution and then only when absolutely necessary to any patient who has a history of some form of allergy, particularly to drugs.

The normal flora of the colon is altered by treatment with broad spectrum antibiotics and this may permit overgrowth of clostridia. Studies indicate that one primary cause of antibiotic-associated colitis is a toxin produced by *Clostridium difficile*.

With the use of cephalosporins and other broad spectrum antibiotics, pseudomembranous colitis has been reported. It is therefore important to consider its diagnosis in patients who develop diarrhea in association with antibiotic use.

Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe cases should be managed with fluid, electrolyte and protein supplementation as indicated. When the colitis is not relieved by drug discontinuance or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis. Other causes of colitis

should also be considered.

**Susceptibility/Resistance:
Development of Drug-Resistant Bacteria**

Prescribing APO-CEFADROXIL in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of resistant drug-resistant bacteria.

Potential for Microbial Overgrowth

Prolonged use of APO-CEFADROXIL can result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, the administration of APO-CEFADROXIL should be discontinued and appropriate measures taken. An alternate therapy should be instituted if an organism becomes resistant during **treatment** with APO-CEFADROXIL

PRECAUTIONS

A MINIMUM OF 10 DAYS TREATMENT IS RECOMMENDED FOR INFECTIONS CAUSED BY GROUP A β -HEMOLYTIC STREPTOCOCCI.

Patients should be carefully monitored to detect the development of any adverse effect or other manifestations of drug idiosyncrasy. If an allergic reaction to APO-CEFADROXIL (cefadroxil) occurs, its administration should be discontinued and the patient treated with the usual agents (e.g. epinephrine, other pressor amines, or corticosteroids).

APO-CEFADROXIL should be used with caution in the presence of markedly impaired renal function (i.e. a creatinine clearance rate of less than 0.85 mL/sec/1.73 m² (50 mL/min/1.73 m²), (See DOSAGE AND ADMINISTRATION). In patients with known or suspected renal impairment careful clinical evaluation and appropriate laboratory studies should be performed prior to and during therapy, since cefadroxil can accumulate in serum and tissues.

If APO-CEFADROXIL is to be used for long-term therapy, hematologic, renal and hepatic functions should be monitored periodically.

During treatment with the cephalosporin antibiotics, positive direct Coombs tests have been reported. In hematologic studies or in transfusion cross-matching procedures, when antiglobulin tests are performed on the minor side or in Coombs testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be noted that a positive Coombs test may be due to the drug.

During treatment with cefadroxil, a false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution or with Clinistix tablets, but not with enzyme-based tests such as Clinistix or Tes-Tape.

Use in Pregnancy:

The safety of cefadroxil in the treatment of infections during pregnancy has not been established. Therefore, during pregnancy the administration of APO-CEFADROXIL is not

recommended. If in the opinion of the attending physician, the administration of APO-CEFADROXIL is necessary, its use requires that the anticipated benefits be weighed against the possible hazards to the fetus.

Nursing Mothers:

Cephalosporin antibiotics are excreted in human breast milk and therefore, would be ingested by the neonate during breast feeding. Nursing mothers receiving APO-CEFADROXIL should discontinue breast-feeding.

ADVERSE REACTIONS

Adverse reactions observed during use of cefadroxil include:

Gastrointestinal: The most frequently observed have been nausea and vomiting. The incidence and severity are dose dependent and the latter has been severe enough to warrant cessation of therapy, but infrequently.

Other reactions reported were abdominal cramps, gastric upset, heartburn, gas and diarrhea.

Hypersensitivity: Rash, swollen and running eyes, urticaria, eosinophilia, angioedema and positive direct Coombs test.

Central Nervous System:

Dizziness, weakness, drowsiness, vertigo, nervousness and headaches.

Miscellaneous: Vaginitis, monilial vaginitis, vaginal itching, cramps in side and legs, transient neutropenia and elevations in BUN, alkaline phosphatase and AST (SGOT).

These adverse effects were seen during clinical trials in 5.8% of patients.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

There is no specific antidote for overdosage with APO-CEFADROXIL. Therefore, treatment should be symptomatic.

DOSAGE AND ADMINISTRATION

APO-CEFADROXIL (cefadroxil) is administered orally and may be taken without regard to meals.

The incidence and severity of gastrointestinal complaints is dose dependent. Administration with food may be helpful to diminish potential intestinal complaints.

A MINIMUM OF 10 DAYS TREATMENT IS RECOMMENDED FOR INFECTIONS CAUSED BY GROUP A β -HEMOLYTIC STREPTOCOCCI.

ADULTS:

Normal Renal Function: The recommended dose is 1 to 2 g per day.

Urinary Tract Infections:

The recommended daily dose is 1 to 2 g. This may be given as a single dose at bedtime or divided into 500 mg to 1 g doses for twice a day administration (every 12 hours). The usual duration of therapy is 10 days. While shorter or longer courses may be appropriate for some patients, cefadroxil should be administered for a sufficient period of time to render the urine sterile. The sterility of the urine should be re-evaluated 2 to 4 weeks after cessation of therapy.

Acute Pharyngitis and Tonsillitis:

The recommended dose is 1 g per day in single (qd) or divided doses (bid). Treatment should be for a minimum of 10 days and continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.

Lower Respiratory Tract Infections: The recommended dose is 500 mg to 1 g two times per day (every 12 hours).

Skin and Skin Structure Infections: 1 g daily in a single dose.

Impaired Renal Function: The dosage of APO-CEFADROXIL should be adjusted according to creatinine clearance rates to prevent drug accumulation.

In adults the dose is 1 g for a patient with normal renal function (see above) and the maintenance dose (based on the creatinine clearance rate) is 500 mg at the time intervals listed below:

Creatinine Clearance		Dose Interval (hours)
(mL/sec/1.73 m ²)	(mL/min/1.73 m ²)	
0 - 0.17	0 - 10	36
0.17 - 0.43	10 - 25	24
0.43 - 0.85	25 - 50	12

Patients with creatinine clearance rates greater than 0.85 mL/sec/1.73 m² (50 mL/min/1.73 m²) may be dosed as for those patients with normal renal function.

PHARMACEUTICAL INFORMATION


Drug Substance

Common Name: Cefadroxil

Chemical Names:

- 1) 5-Thia-1-azabicyclo[4.2.0]-oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)-acetyl]amino]-3-methyl-8-oxo-, monohydrate, [6*R*-[6 α , 7 β (*R*^{*})]]-
- 2) (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(*p*-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid monohydrate.

Structural Formula:



Molecular Formula: C₁₆H₁₇N₃O₅S•H₂O

Molecular Weight: 381.40 g/mol

Description: A white or off-white crystalline powder. Slightly soluble in water; practically insoluble in alcohol, in chloroform and in ether. Composition

APO-CEFADROXIL (cefadroxil) capsules contain cefadroxil monohydrate equivalent to 500 mg cefadroxil, along with the following non-medicinal ingredients: colloidal silicon dioxide, croscarmellose sodium, stearic acid, talc.

The capsule shell contains the following non-medicinal ingredients: FD&C blue #1, FD&C red #40, gelatin, grey ink, silicon dioxide and titanium dioxide.

The edible grey ink on the capsule shells contains the non-medicinal ingredient black iron oxide.

Stability and Storage Recommendations

Store at room temperature (15° to 30°C), in tightly-closed containers.

AVAILABILITY OF DOSAGE FORMS

APO-CEFADROXIL (cefadroxil) is available as off-white powder in white body, maroon cap hard gelatin capsules imprinted 'APO 500', containing 500 mg of cefadroxil (as monohydrate). Available in bottles of 100 capsules.

MICROBIOLOGY

The antibacterial activity of cefadroxil was determined *in vitro* on 555 strains of gram-negative and gram-positive organisms. These results are outlined in Table I in terms of cumulative percentage as determined by the agar dilution method.

Many strains of *H. influenzae* and most strains of enterococci species (*Strep. faecalis* and *Strep. faecium*), Enterobacter species, indole-positive Proteus species, *Providencia stuartii* and Serratia species are resistant to cefadroxil. Cefadroxil has no activity against Pseudomonas and Herella species.

Table 1												
Organism (No. of Strains)	Cumulative % of Strains Inhibited at Indicated Concentrations (mcg/mL)											
	0.13	0.25	0.50	1	2	4	8	16	32	63	125	250
GRAM-POSITIVE												
<i>Str. Pyogenes</i> (28)	89.2	100	--	--	--	--	--	--	--	--	--	--
<i>Str. Pneumoniae</i> (20)	--	5	20	40	95	100	--	--	--	--	--	--
<i>S. aureus</i> (17) (non-penicillinase producing)	--	--	--	11.7	100	--	--	--	--	--	--	--
<i>S. aureus</i> (10) (penicillinase producing)	--	--	--	--	31.4	85.6	100	--	--	--	--	--
<i>Str. Faecalis</i> (14)	--	--	--	--	--	--	--	7.1	7.1	100	--	--
GRAM-NEGATIVE												
<i>N. gonorrhoeae</i> (16)	--	--	--	12.5	18.7	49.9	81.1	100	--	--	--	--
<i>Shigella</i> sp. (12)	--	--	--	--	--	8.3	74.9	100	--	--	--	--
<i>Salmonella</i> (32)	--	--	--	--	--	--	62.5	96.5	100	--	--	--
<i>K. pneumoniae</i> (62)	--	--	--	--	--	--	56.4	90.2	96.6	98.2	100	--
<i>P. mirabilis</i> (51)	--	--	--	--	--	--	3.90	64.6	97.9	100	--	--
<i>E. coli</i> (96)	--	--	--	--	--	6.2	54.1	90.5	92.5	96.6	96.6	96.6
<i>H. influenzae</i> (24)	--	--	--	--	--	--	--	20.9	95.9	100	--	--
<i>P. stuartii</i> (31)	--	--	--	--	--	--	3.2	12.8	38.6	67.0	96.6	100
<i>P. vulgaris</i> (4)	--	--	--	--	--	--	--	25.0	50.0	50.0	75.0	100

In Vivo Studies

Male Swiss-Webster mice were fasted overnight and then challenged by the intraperitoneal injection of sufficient pathogens to kill untreated animals within 72 hours. The challenge organisms included *Str. pyogenes*, *Str. pneumoniae*, *S. aureus*, *E. coli*, *K. pneumoniae* and *P. mirabilis*. Cefadroxil was given orally at the time of infection and repeated 2 hours later for *S. aureus* infections. In the case of the other organisms, cefadroxil was given orally at 1 and 3.5 hours after injection of the bacteria. The results are summarized in Table II.

Table II Protective Activity of Cefadroxil in Mice		
Organism (No. of Strains)	Challenge (Mean # of organisms)	Protective Dose ₅₀ (mg/kg)
<i>Str. pyogenes</i> (3)	6.7×10^6	1.23
<i>Str. pneumoniae</i> (3)	2.0×10^5	22.0
<i>S. aureus</i>		
• lacking penicillinase (2)	1.5×10^8	2.7
• with penicillinase (2)	1.0×10^9	18.5
<i>E. coli</i> (2)	6.0×10^4	14.0
<i>K. pneumoniae</i> (1)	4.0×10^4	85.0
<i>P. mirabilis</i> (1)	3.0×10^6	64.0

Male Swiss-Webster mice were challenged by injecting *P. mirabilis* into the right hind leg muscle only (0.2 mL of a suspension containing 10^8 organisms). Immediately following the bacterial challenge, cefadroxil was administered either orally or subcutaneously and thigh enlargement was measured 24 hours later. When administered by the oral route, cefadroxil had an ED₅₀ of 85 mg/kg; the ED₅₀ was 80 mg/kg by the subcutaneous route.

β Lactamase Susceptibility

The susceptibility of cefadroxil to hydrolysis by cell-free extracts containing different β-lactamases is shown in Table III.

Table III Relative Susceptibility to Hydrolysis by Beta-Lactamases			
Enzyme		Organism (Source of Enzyme)	Relative Rate of Hydrolysis*
Class	Type		

I	a	<i>Enterobacter cloacae</i>	595
	b	<i>Escherichia coli</i>	48
II	a	<i>Proteus mirabilis</i>	<1
III	a	<i>E. coli</i>	<1
IV	a	<i>Klebsiella pneumoniae</i>	<1
	b	<i>K. pneumoniae</i>	2
--	--	<i>Staphylococcus aureus</i> (A9606)	<1

*Benzyl penicillin = 100

PHARMACOLOGY

Animal:

After oral administration of cefadroxil at 50 mg/kg to four groups of rats (sampling was performed at 0.5, 1, 2 and 4 hours), maximum concentrations were reached at 0.5 hours in the liver (18.9 mcg/g), kidney (136 mcg/g) and muscle (4.88 mcg/g) and at 1 hour in the lungs (5.63 mcg/g), spleen (3.88 mcg/g) and heart (2.63 mcg/g). In the brain insignificant concentrations were seen (0.83 mcg/g).

Human:

Following oral administration, cefadroxil is well absorbed, with 93% of a 500 mg dose being recovered unchanged in the urine after 24 hours. The presence of food does not inhibit the absorption of cefadroxil from the gastrointestinal tract.

Approximately 20% of the dose of cefadroxil is bound to the serum proteins. The apparent volume of distribution is 14 to 17% of body weight.

Following single oral doses the total urinary excretion of cefadroxil has been determined in a number of experiments. The results are summarized in Table IV.

Table IV				
Dose of Cefadroxil (mg)	Cumulative Urinary Excretion (mg)			
	0-3 hr.	3-6 hr.	6-12 hr.	Total 0-12 hr.
500	290	115	44	449
1000	455	264	111	830

The following table (Table V) shows various pharmacokinetic values for 500, 1000 and 2000 mg doses.

Table V Pharmacokinetic Parameters in Normal Human Volunteers			
Parameter	Dose of Cefadroxil (mg)		
	500	1000	2000
Time to peak concentration: T_{max} (hr)	1.28	2.00	2.00
Peak concentration: C_{max} (mcg/mL)	14.8	23.63	32.7
Area under the curve: AUC (mcg/hr/mL)	45.3	94.20	167.42
Half-life (hr)	1.34	1.51	--

Lower Respiratory Tissue Levels

Seven patients received cefadroxil as a 500 mg single dose. At 12 hours, the pleural exudate contained cefadroxil at a level of 2.1 mcg/mL compared to 0.8 mcg/mL in the serum. The pleural fluid concentration after 8 hours and 12 hours following the administered dose is shown in Table VI.

Table VI Pleural Fluid Concentration Following a Single 500 mg Oral Dose of Cefadroxil			
No. of Cases	Time (hrs) Post-Dose	Cefadroxil Conc.	
		Pleural Fluid (mcg/mL)	Serum (mcg/mL)
7	8	3.6	3.4
	12	2.1	0.8

In another study, following a single 1 g dose of cefadroxil, the mean pleural exudate and mean serum levels demonstrated a similar pattern 3 to 5 hours post administration i.e. the pleural fluid concentration is higher than the serum concentration (Table VII).

Table VII Measurement of Cefadroxil in Respiratory Tissues and Fluids Following a Single 1 g Dose				
Fluid or Tissue	No. of Cases	Time (hrs) Post-Dose	Cefadroxil Conc.	
			Fluids (mcg/mL) Tissue (mcg/g)	Serum (mcg/mL)
Sputum	9	3-4	1.3	Not done
Pleural Exudate	4	3-5	11.4	9.4
Lungs	22	2-4	7.4	11.5

Results from Table VI and Table VII indicate that tissue and fluid compartments act as a depot for cefadroxil after serum concentrations have diminished.

Renal Impairment

Twenty fasting patients with varying degrees of renal impairment as determined by creatinine

clearance (from anuric to 1.76 mL/sec/1.73 m² (105.7 mL/min/1.73 m²)) were administered single 1000 mg doses of cefadroxil. Blood and urinary concentrations of cefadroxil were monitored for up to 48 hours after drug administration. The results of this study show that as creatinine clearance decreases the elimination rate constant also decreases but the half-life increases.

In another study, eight fasting patients with varying degrees of severe renal impairment were administered single 1000 mg doses of cefadroxil. Creatinine clearances varied from 0.004 to 0.54 mL/sec/1.73 m² (0.24 to 32.35 mL/min/1.73 m²). Blood and urinary concentrations of cefadroxil were monitored for up to 48 hours after drug administration. A linear inverse correlation between the half-life of cefadroxil and creatinine clearance was observed.

TOXICOLOGY

Acute Toxicity:

The LD₅₀ values (See Table VIII) were determined for cefadroxil in mice and rats. The observation period after the single injection was 7 days.

Table VIII					
Species	Age	Sex	No. of Animals	Route of Admin.	LD ₅₀ (mg/kg)
Mouse*	Adult	M&F	80	p.o.	>7000
Mouse*	Adult	M&F	80	i.p.	>7000
Mouse	Adult	M&F	40	i.v.	>1500
Mouse	Adult	M&F	60	s.c.	>5000
Rat	24-48 hrs.	M&F	50	p.o.	>8000
Rat**	Adult	M&F	60	p.o.	>8000
Rat**	Adult	M&F	60	i.p.	>6000
Rat**	Adult	M&F	40	i.v.	>1000
Rat**	Adult	M&F	40	s.c.	>5000

*Swiss-Webster mice; **Sprague-Dawley rats.

There were no deaths observed in mice or in young rats. In adult rats, one death occurred following an intraperitoneal dose of 6000 mg/kg and 3 deaths following an intravenous dose of 1000 mg/kg. At high doses, ataxia, decreased activity and prostration were observed.

Two adult beagle dogs (one male and one female) received cefadroxil orally at a dose of 500 mg/kg. One of the animals exhibited emesis and slight drowsiness while the other exhibited moderate drowsiness and had a slight increase in the heart rate.

Subacute Toxicity:

Four groups of 30 Sprague-Dawley rats (15 males and 15 females) received cefadroxil administered orally at doses of 0, 200, 400 or 600 mg/kg/day for 14 weeks. In males dosed at

400 and 600 mg/kg liver weights were increased by 11% and the combined relative weights of seminal vesicles and prostate glands were decreased by 16 to 21% for all treated groups. Adrenal weights of females in the 400 and 600 mg/kg groups were decreased by 12 to 16%. At autopsy no histological abnormalities were observed.

Three groups of 10 male and 10 female weanling rats were administered cefadroxil, by gavage, at doses of 0, 2000 or 4000 mg/kg/day for 4 weeks. An increase in SGPT (112%) in half of the animals in the 2 treated groups; a slight decrease in serum protein levels in both treated groups; and a decrease in serum glucose values in the high dose groups were observed. At necropsy increased cecum size (1.5 to 3 fold), and decreased heart (10.5 to 15.9%), liver (4.9 to 6.1%) and spleen (10.8 to 25.7%) weights were seen, although no histological changes in the organs were noted.

Cefadroxil was administered orally at doses of 0, 100, 200 or 400 mg/kg/day to four groups of young beagle dogs (3 males and 3 females per group) for a period of 13 weeks. By the end of the study, the animals in the 200 and 400 mg/kg/dose groups had a marginally lower food intake (10 to 18%) and body weight (6.8%). At autopsy, no histological abnormalities were observed. However, in the high dose group, the spleen and gonad weights in female dogs were elevated (78% and 88%, respectively) while in the 200 mg/kg dose group, the relative adrenal weights were increased by 45%. At all drug dose levels, there was an increased incidence of emesis (dose related) and proteinuria.

Chronic Toxicity:

Four groups of 30 Charles River rats (15 males and 15 females) received cefadroxil administered orally (admixed in the feed) at doses of 0, 100, 316 or 1000 mg/kg/day for a period of 26 weeks. There were no deaths, however, significantly increased ($p < 0.05$) kidney weights in the middle (11%) and high (16%) dose group males were observed.

Cefadroxil was administered to four groups of beagle dogs (3 males and 3 females) at doses of 0, 200, 400 or 600 mg/kg/day for 26 weeks (once a day for the first week, then twice daily for the remainder of the experiment). A decrease was seen in weight gain (24.6%) in the middle dose female group and in all treated groups a slight decrease in total serum proteins and albumin levels were observed.

Renal Toxicity:

Male mice were pretreated with intraperitoneal injections of furosemide (20 or 40 mg/kg) or 0.9% saline. Fifteen minutes later they were injected intraperitoneally with 0.9% saline or doses of 1396, 2792 or 5584 mg/kg of cefadroxil. Forty-eight hours following the injections, urine evaluation (pH, glucose and urine protein) and histological examination of kidneys were conducted. A slight weight loss in the high dose cefadroxil group pretreated with furosemide was noted. No evidence of renal injury was observed.

Fertility and Reproduction Study:

Cefadroxil administered orally at doses of 0, 200 or 400 mg/kg/day during gestation to three groups of 40 Sprague-Dawley rats per group (15 males and 25 females) did not modify pregnancy nor alter the percentage of resorptions. The males were dosed for 77 days prior to mating and the females for 14 days prior to mating. The percentage of stillbirths in each group was 3.3, 1.8 and 1.3 for the 400, 200 and 0 mg/kg dose groups, respectively.

Teratology Studies:

No discernible effect on nidation or on maternal or fetal survival was found after the oral administration of cefadroxil at doses of 0, 100, 250 or 500 mg/kg/day given b.i.d. to pregnant Sprague-Dawley rats and Swiss mice on gestation day 6 through day 15.

Perinatal - Postnatal Study:

Pregnant Sprague-Dawley rats received cefadroxil administered in doses of 0, 250 or 500 mg/kg/day given b.i.d. from day 14 of gestation to post-partum day 21. There were no adverse drug related effects on fetal birth weight, survival or growth observed.

BIBLIOGRAPHY

1. Ballantyne FN. Comparative efficacy of cefadroxil and cefaclor in the treatment of skin and soft-tissue infections. *Clin Ther* 1985; 7: 487-91.
2. Beisel L. Efficacy and safety of cefadroxil in bacterial pharyngitis. *J Int Med Res* 1980; 8(Suppl. 1): 87-93.
3. Bernhardt LL. Tissue and fluid concentrations of cefadroxil monohydrate. *J Int Med Res* 1980; 8(Suppl. 1): 58-63.
4. Blaser MJ, Klaus BD, Jacobson JA, et al. Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia. *Antimicrob Agents Chemother* 1983; 24: 163-7.
5. Buck RE, Price KE. Cefadroxil, a new broad-spectrum cephalosporin. *Antimicrob Agents Chemother* 1977; 11(2): 324-330.
6. Castro M. A comparative study of cefadroxil and co-trimoxazole in patients with lower respiratory tract infections. *Drugs* 1986; 32 (Suppl. 3): 50-6.
7. Cutler RE, Blair AD, Kelly MR. Cefadroxil kinetics in patients with renal insufficiency. *Clin Pharmacol Ther* 1979; 25: 514-21.
8. Gerber MA. A comparison of cefadroxil and penicillin V in the treatment of streptococcal pharyngitis in children. *Drugs* 1986; 32 (Suppl. 3): 29-32
9. . Hartstein AI, Patrick KE, Jones SR, Miller MJ, Bryant RE. Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin. *Antimicrob Agents Chemother* 1977; 12(1): 93-97.
10. Hickey TE, Botta Jr JA, Clemento Jr AJ. Cefadroxil - a new antibiotic with low toxicity potential. *Curr Ther Res* 1978; 23(5): 608-616.
11. Jolly ER, Henness DM, Richards Jr D. Human safety, tolerance and pharmacokinetic studies of cefadroxil - a new cephalosporin antibiotic for oral administration. *Curr Ther Res* 1977; 22(5): 727-736.
12. Kafetzis, DA, Sifas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into the breast milk. *Acta Paediatr Scand* 1981; 70: 285-8.
13. Lode H, Stahlmann R, Koeppe P. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil and CGP 9000. *Antimicrob Agents Chemother* 1979; 16(1): 1-6.
14. Nightingale CH. Penetration and concentration of cefadroxil in sputum, lung and pleural fluid. *Drugs* 1986; 32 (Suppl 3): 17-20.
15. Pfeffer M, Jackson A, Ximenes J, Perche de Menezes J. Comparative human oral clinical pharmacology of cefadroxil, cephalexin and cephradine. *Antimicrob Agents Chemother* 1977; 11(2): 331-338.
16. Quintiliani R. Efficacy of a twice-daily regimen of cefadroxil in the treatment of respiratory tract infections. *Drugs* 1986; 32 (Suppl. 3): 43-9.

17. Sandberg T, Henning C, Iwarson S, Paulsen O. Cefadroxil once daily for three or seven days versus amoxicillin for seven days in uncomplicated urinary tract infections in women. *Scand J Infect Dis* 1985; 17: 83-7.
18. Santella PJ, Berman E. Cefadroxil - sustained antimicrobial effect in bacterial infections. A review of clinical studies. *Curr Ther Res* 1978; 23(2): 148-158.
19. Santella PJ, Tanrisever B, Berman E. An overview of results of world-wide clinical trials with cefadroxil. *J Int Med Res* 1978; 6: 441-451.
20. Tanrisever B, Santella PJ. Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. *Drugs* 1986; 32 (Suppl. 3): 1-16.
21. Tzias V, Dontas AS, Petrikos G, et al. Three-day antibiotic therapy in bacteriuria of old age. *J Antimicrob Chemother* 1990; 26: 705-11.
22. Wilson JP, Koren JF, Daniel RC, Chapman SW. Cefadroxil-induced ampicillin-exacerbated pemphigus vulgaris: case report and review of the literature. *Drug Intel Clin Pharm* 1986; 20: 219-23.
23. ZeLuff B, Catchpole M, Lowe P, et al. Cefadroxil compared with cefaclor in the treatment of streptococcal pneumonia in adults. *Drugs* 1986; 32(Suppl.3): 39-42.
24. AHFS Drug Information 1995, American Society of Hospital Pharmacists Inc., Bethesda, MD, U.S.A., 98-106.
25. Martindale, The Extra Pharmacopoeia, 30th Edition. The Royal Pharmaceutical Society of Great Britain. London, England, 1993, p 127.
26. Physicians' Desk Reference, 48th Edition, 1994, N.J. U.S.A., pp. 1799-800.
27. Product Monograph for Duricef® (Cefadroxil). Bristol Laboratories of Canada, Ottawa, ON. August 7, 1987.
28. Product Monograph TEVA-CEFADROXIL, Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada, M1B 2K9 Date of Revision: July 16, 2018 Control Number: 211316.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

^{Pr} **APO-CEFADROXIL**

Cefadroxil Capsules USP

500mg

Read this carefully before you start taking APO-CEFADROXIL and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about APO-CEFADROXIL.

What is APO-CEFADROXIL used for?

APO-CEFADROXIL is used to treat infections caused certain bacteria in the:

- Urinary tract.
- Skin.
- Throat (including Pharyngitis and/or tonsillitis).
- Lungs (including pneumonia).

Antibacterial drugs like APO-CEFADROXIL treat only bacterial infections. They do not treat viral infections.

How does APO-CEFADROXIL work?

APO-CEFADROXIL is an antibiotic, which belongs to a class of drugs called cephalosporins. APO-CEFADROXIL works by killing bacteria which cause infections in the body.

What are the ingredients in APO-CEFADROXIL?

Medicinal ingredients: Cefadroxil

Non-medicinal ingredients: Colloidal silicon dioxide, croscarmellose sodium, stearic acid, talc.

The capsule shell contains the following non-medicinal ingredients: FD&C blue #1, FD&C red #40, gelatin, grey ink, silicon dioxide and titanium dioxide.

The edible grey ink on the capsule shells contains the non-medicinal ingredient black iron oxide.

APO-CEFADROXIL comes in the following dosage forms:

APO-CEFADROXIL (cefadroxil) is available as off-white powder in white body, maroon cap hard gelatin capsules imprinted 'APO 500', containing 500 mg of cefadroxil (as monohydrate). Available in bottles of 100 capsules.

Do not use APO-CEFADROXIL if:

Do not take APO-CEFADROXIL if you have had an allergic reaction to APO-CEFADROXIL or other medicines such as cephalosporins.

Before starting APO-CEFADROXIL and to get the best possible treatment, be sure to tell your doctor if you:

- Have had an allergic reaction to APO-CEFADROXIL or other medicines such as penicillins;
- Have severe kidney disease with or without significant liver disease;
- Are pregnant or could become pregnant during treatment;
- Are breast feeding or planning to breast

feed. Other warnings that you should know about:

APO-CEFADROXIL may cause inflammation of the colon (colitis), with symptoms such as diarrhea. Talk to your doctor if you experience any intestinal side effects.

APO-CEFADROXIL may affect the results of urine tests. Talk to your healthcare professional if you take any urine tests while taking APO-CEFADROXIL.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How to take APO-CEFADROXIL:

- APO-CEFADROXIL may be taken with or without food. Taking APO-CEFADROXIL may help reduce intestinal issues.
- Although you may feel better early in treatment, APO-CEFADROXIL should be used exactly as directed.
- Misuse or overuse of APO-CEFADROXIL could lead to the growth of bacteria that will not be killed by APO-CEFADROXIL (resistance). This means that APO-CEFADROXIL may not work for you in the future.
- Do not share your medicine.

Usual Adult Dose:

Your doctor will tell you how much APO-CEFADROXIL to take. Your dose may be 2 to 4 capsules per day, depending on your condition.

Overdose:

If you think you have taken too much APO-CEFADROXIL, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms.

What are possible side effects from using APO-CEFADROXIL?

These are not all the possible side effects you may feel when taking APO-CEFADROXIL. If you experience any side effects not listed here, contact your healthcare professional.

- rash
- abdominal cramps
- upset stomach
- heartburn
- flatulence (gas)

- dizziness
- weakness
- drowsiness
- nervousness
- headache

Serious side effects and what to do about them

Symptom / effect		Talk to your healthcare professional		Stop taking drug and get immediate medical help
		Only if severe	In all cases	
Uncommon	An allergic reaction (difficulty in breathing, closing of the throat, swelling of the lips, face or tongue; hives or a rash			√
	Redness, or itching			√
	Severe nausea, vomiting, or diarrhea			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

How to store APO-CEFADROXIL:

Store at room temperature (15° to 30°C), in tightly-closed containers. Keep out of reach and sight of children.

If you want more information about APO-CEFADROXIL:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this patient medication information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); Find the Patient Medication Information on the manufacturer's website <http://www.apotex.ca/products>, or by calling 1-800-667-4708.

This leaflet was prepared by
Apotex Inc.
Toronto, Ontario
M9L 1T9.

Last Revised: September 1, 2020